![Eran Ophir](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Eran Ophir
Directeur Général chez
COMPUGEN LTD.
Fortune : 26 731 $ au 31/07/2026
Profil
Eran Ophir is the founder of Compugen USA, Inc. Dr. Ophir is currently President, Chief Executive Officer & Director at Compugen Ltd. since 2025.
Education includes an undergraduate degree from Tel-Aviv University and a doctorate from the Weizmann Institute of Science.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
COMPUGEN LTD. 0,01 % | 29/07/2026 | 11 375 ( 0,01 % ) | 26 731 $ | 31/07/2026 |
Postes actifs de Eran Ophir
| Sociétés | Poste | Début |
|---|---|---|
| COMPUGEN LTD. | Directeur Général | 23/09/2025 |
Compugen Usa, Inc.
 Compugen Usa, Inc. Information Technology ServicesTechnology Services The company is based in San Francisco, CA. Part of Compugen Ltd., Compugen USA, Inc. is a clinical-stage biopharmaceutical company specializing in cancer immunotherapies. The company leverages a proprietary AI-powered predictive computational discovery platform called Unigen™, which integrates multi-omics, single-cell RNA sequencing, spatial omics, and machine learning to identify novel drug targets and biological pathways. This platform enables the discovery and development of immuno-oncology therapeutics aimed at patients unresponsive to existing treatments. Compugen’s pipeline features multiple antibody candidates, including COM701 (anti-PVRIG), COM902 (a high-affinity Fc-reduced anti-TIGIT antibody), GS-0321 (anti-IL18BP), and Rilvegostomig (an Fc-reduced anti-PD1/TIGIT bispecific antibody), which are advanced through clinical trials across cancer indications such as non-small-cell lung, gastrointestinal, and endometrial cancers. The company engages in strategic collaborations, including an exclusive license agreement with AstraZeneca for TIGIT-targeting antibodies and a license agreement with Gilead for anti-IL-18 binding protein antibodies. | Directeur Général | - |
Formation de Eran Ophir
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
34
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Compugen Ltd.
 Compugen Ltd. BiotechnologyHealth Technology Discovers and researches drug & diagnostics | Health Technology |
Tel-Aviv University
 Tel-Aviv University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Weizmann Institute of Science
 Weizmann Institute of Science Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Compugen Usa, Inc.
Compugen Usa, Inc. Information Technology ServicesTechnology Services The company is based in San Francisco, CA. Part of Compugen Ltd., Compugen USA, Inc. is a clinical-stage biopharmaceutical company specializing in cancer immunotherapies. The company leverages a proprietary AI-powered predictive computational discovery platform called Unigen™, which integrates multi-omics, single-cell RNA sequencing, spatial omics, and machine learning to identify novel drug targets and biological pathways. This platform enables the discovery and development of immuno-oncology therapeutics aimed at patients unresponsive to existing treatments. Compugen’s pipeline features multiple antibody candidates, including COM701 (anti-PVRIG), COM902 (a high-affinity Fc-reduced anti-TIGIT antibody), GS-0321 (anti-IL18BP), and Rilvegostomig (an Fc-reduced anti-PD1/TIGIT bispecific antibody), which are advanced through clinical trials across cancer indications such as non-small-cell lung, gastrointestinal, and endometrial cancers. The company engages in strategic collaborations, including an exclusive license agreement with AstraZeneca for TIGIT-targeting antibodies and a license agreement with Gilead for anti-IL-18 binding protein antibodies. | Technology Services |
